Identifying Potential Drug Targets and Biomarkers for Neurological and Cardiovascular Diseases

Target Name: ASS1P12

NCBI ID: G392302

ASS1P12

Other Name(s): argininosuccinate synthetase 1 pseudogene 12 | ASSP12 | Argininosuccinate synthetase 1 pseudogene 12

Identifying Potential Drug Targets and Biomarkers for Neurological and Cardiovascular Diseases

Argininosuccinate synthetase (AS) is a key enzyme involved in the production of arginine, a crucial amino acid that plays a vital role in various cellular processes. Mutations in the AS gene have been linked to various neurological and cardiovascular diseases, including amyotrophic lateral sclerosis (ALS), parkinson's disease, and heart failure. Therefore, identifying potential drug targets and biomarkers for these conditions is of great interest.

ASS1P12, a pseudogene located on chromosome 12, has been identified as a potential drug target and biomarker for several neurological and cardiovascular diseases. In this article, we will discuss the structure, function, and potential clinical applications of ASS1P12.

Structure and Function

ASS1P12 is a single-chain protein with 123 amino acid residues. The protein has a molecular weight of 18.1 kDa and a pre-membrane N-terminal region and a C-terminal region with a catalytic active site. The catalytic active site is located at the center of the protein and is responsible for the binding of arginine precursors.

The function of ASS1P12 is to catalyze the conversion of arginine precursors, such as L- arginine and F- arginine, to arginine via a Michaelis-Menten type mechanism. This reaction is critical for the production of arginine, which is then involved in various cellular processes, including the production of nitric oxide, Angiotensin-converting enzyme (ACE), and insulin.

Mutations in the AS gene have been linked to various neurological and cardiovascular diseases, including ALS, Parkinson's disease, and heart failure. Therefore, there is a growing interest in identifying potential drug targets and biomarkers for these conditions.

Potential Clinical Applications

The identification of potential drug targets and biomarkers for neurological and cardiovascular diseases is of great interest, as these conditions can be treated with drugs that target specific proteins involved in the disease process.

One of the potential drug targets for ALS is ASS1P12. The progressive neurodegeneration associated with ALS is thought to be caused by the accumulation of misfolded proteins, including the neurotoxin tau. The misfolding of proteins can be caused by various factors, including genetic mutations, such as those in the AS gene.

Assessing the effectiveness of drugs targeting ASS1P12 may provide valuable insights into the treatment of ALS. Additionally, the development of biomarkers that can predict the response to drugs targeting ASS1P12 may have implications for the early diagnosis and prognosis of this disease.

Parkinson's disease is another neurological disorder that is potentially treatable with drugs that target the misfolded proteins that cause the disease. The accumulation of dopamine-synthesizing enzymes, including the enzyme AS, in Parkinson's disease cells has been linked to the production of dopamine, which is a key neurotransmitter involved in the symptoms of the disease.

Targeting ASS1P12 with drugs that modulate the activity of this enzyme may be a promising approach to the treatment of Parkinson's disease.

Heart failure is a condition that can be treated with drugs that improve cardiac function and reduce the workload on the heart. The production of arginine by the enzyme AS is critical for cardiac function, and targeting this enzyme with drugs that enhance its activity may have implications for the treatment of heart failure.

In conclusion, the identification of potential drug targets and biomarkers for neurological and cardiovascular diseases, such as ALS, Parkinson's disease, and heart failure, is of great interest. The enzyme ASS1P12, in particular, has been identified as a potential drug target and biomarker for

Protein Name: Argininosuccinate Synthetase 1 Pseudogene 12

The "ASS1P12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASS1P12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets